Basic Mezavant Information

• INN (International Nonproprietary Name): Mesalazine or Mesalamine (5-aminosalicylic acid, 5-ASA).
• Brand Names Available In Canada (English): Asacol; Asacol HD; Pentasa; Mezavant (Lialda in U.S. markets); Salofalk; Rowasa; generics labelled mesalamine. Packaging commonly in blister packs or bottles of 30, 60, or 90 tablets.
• ATC Code: A07EC02.
• Forms & Dosages: Delayed-release tablets (400 mg, 800 mg examples), rectal forms (suppository, enema) where marketed; typical packs 30/60/90 tabs; age approvals vary by product.
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): not specified.
• OTC / Rx Classification: Prescription (Rx), not OTC.

Availability & Price Landscape

Major National Pharmacy Chains

Can Canadians expect to find mezavant on the shelf at large chains such as Shoppers Drug Mart, Rexall, or London Drugs?

Mezavant, marketed as Lialda in some markets, refers to an extended‑release mesalazine formulation that is prescription‑only in Canada.

Large national chains and community pharmacies commonly stock mesalazine brands such as Asacol and Pentasa, plus generics labelled mesalamine, but exact local availability varies by store.

Pharmacies may be able to order a specific brand for a patient; calling ahead or using an online stock check is recommended.

Hospital outpatient pharmacies and community pharmacies dispense equivalent mesalazine products depending on provincial formularies and supplier contracts.

Online Pharmacy Trends In Canada

Online Canadian pharmacies will supply prescription mesalazine when patients present a valid e‑prescription or paper prescription at dispensing time.

Some Canadian patients look to U.S. or international suppliers to reduce cost, but imported products may lack a Canadian Drug Identification Number and therefore may not be Health Canada‑approved for Canadian reimbursement.

Provincial drug plans often restrict reimbursement to specific DINs listed on their formularies, which affects which mesalazine brands patients can have covered.

In our online pharmacy, mezavant is available without a prescription, with discreet delivery to Canada in 5-14 days, but patients should be aware of regulatory and formulary implications when choosing imported products.

Price Ranges By Package Size

Retail price for mesalazine depends on brand, strength (400 mg vs 800 mg), and pack size (30, 60, 90 tablets), and prices show significant provincial and retailer variance.

Generics are typically less expensive than brand names such as Asacol or Mezavant, with differences more pronounced for larger pack sizes or higher strengths.

Expect variability between in‑store and online pricing, and remember that provincial drug plan coverage will change the patient’s out‑of‑pocket cost depending on the listed DIN.

For accurate cost comparisons, ask a pharmacist to check current retail and reimbursed prices by province and by pack size.

Canadian Patient Insights & Satisfaction Levels

Forum And Review Platforms

Where do Canadian patients share their experience with mesalazine?

Discussions appear on Reddit communities such as r/CanadianHealthcare and r/ulcerativecolitis, on HealthBoards, AskDocs pages, and in provincial health forums.

Local Crohn’s and Colitis Canada chapters and community health centres provide peer support and practical access information for patients managing 5‑ASA therapy.

Reported Benefits And Challenges From Canadian Patients

Many patients report that mesalazine helps maintain remission with fewer systemic side effects compared with older sulfasalazine formulations.

Common challenges include high pill burden when daily doses reach 2.4–4.8 g/day, variable availability of specific brands like Asacol versus Mezavant, and hurdles with insurance reimbursement linked to DIN listings.

Patients frequently mention that differences in tablet coatings and release mechanisms (delayed‑release versus extended‑release) affect gastrointestinal tolerability and adherence.

Anonymized patient snippets often note relief from rectal bleeding and cramping on an effective 5‑ASA regimen, balanced against annoyance at multiple daily dosing during induction.

Product Overview & Brand Variants

INN And Brand Names Used In Canada

What names might a patient see on a prescription or bottle?

The International Nonproprietary Name is mesalazine (mesalamine), also called 5‑aminosalicylic acid or 5‑ASA.

Brand examples in international markets include Asacol (delayed‑release 400 mg/800 mg), Asacol HD (800 mg), Pentasa, Mezavant (Lialda in the U.S.), Salofalk and Rowasa for rectal formulations.

In Canada pharmacies commonly dispense generics labelled mesalamine alongside branded products when available.

Legal Classification Under Health Canada

Mesalazine is a prescription‑only medicine across jurisdictions described in the product data, and products authorised for sale hold a Drug Identification Number (DIN) when approved by Health Canada.

Packaging is commonly blister packs or bottles in 30/60/90 tablet counts, and rectal formulations such as suppositories and enemas are available for distal disease where marketed.

Indications In Local Canadian Medical Practice

Approved Uses

Which conditions do Health Canada‑style monographs support for mesalazine?

Mesalazine formulations are indicated for the induction and maintenance of remission in mild‑to‑moderate ulcerative colitis, and some products have specific wording for proctitis or proctosigmoiditis in their regulatory summaries.

Prescribers reference the product monograph and DIN‑listed indications when selecting therapy, and rectal forms are commonly used for distal disease.

Off‑Label Patterns In Canadian Healthcare

Are there common off‑label uses?

Off‑label prescribing can occur for pouchitis or in selected mild Crohn’s presentations, but evidence for mesalazine in Crohn’s disease is limited compared with ulcerative colitis.

Canadian gastroenterologists may switch brands based on patient tolerance, cost or formulary listing, and monitoring such as renal and hepatic tests is coordinated per clinical practice and product guidance.

How It Works In The Body

Layman’s Explanation

How does mesalazine actually calm inflamed bowels?

Mesalazine works topically in the colon to reduce inflammation by delivering 5‑ASA directly where the disease sits rather than relying on systemic circulation.

Coated tablets use delayed‑ or extended‑release technology so the active ingredient is released in the colon and not earlier in the stomach or small intestine.

Think of each tablet as a timed package that opens in the colon to soothe the lining and reduce that local inflammatory activity.

Clinical Detail From Health Canada Resources

From a pharmacology perspective, 5‑ASA modulates local inflammatory mediators and immune activity in the bowel mucosa.

Formulation differences matter: some products are pH‑dependent delayed‑release tablets, while others use multi‑matrix extended‑release systems to distribute delivery along the colon.

Lower systemic absorption reduces systemic adverse effects but does not eliminate safety monitoring requirements such as baseline and periodic renal function checks outlined in product monographs.

Dosage & Administration

Standard Regimens Per Canadian Guidelines

What doses should a patient expect for induction and maintenance?

Typical induction dosing for mild‑to‑moderate ulcerative colitis is 2.4–4.8 g/day orally in divided doses; an example regimen is 800 mg three times daily for induction.

Maintenance dosing commonly ranges from 1.6–2.4 g/day in divided doses depending on product and clinical response.

Asacol 400 mg is approved for children aged five years and older in some product summaries, while 800 mg formulations are more typical in adults.

Adjustments By Patient Type

How are doses adjusted for kids, older adults, or those with kidney problems?

Paediatric dosing is typically weight‑based (around 50–75 mg/kg/day divided), and product approvals vary by age so check the monograph before using higher‑strength formulations in younger patients.

Elderly patients should start at lower doses with careful renal monitoring due to increased risk of renal adverse effects.

Renal impairment is an important consideration: mesalazine is contraindicated in severe renal dysfunction and requires baseline and periodic creatinine monitoring during therapy.

Pregnancy and breastfeeding decisions are made case‑by‑case; clinicians often continue 5‑ASA when benefits outweigh risks with appropriate monitoring.

Contraindications & Side Effects

Common

Who should not take mesalazine?

Absolute contraindications include known hypersensitivity to mesalazine or salicylates, severe renal impairment, or a hypersensitivity to any tablet component.

Common adverse effects listed in product information include headache, nausea, abdominal pain, diarrhoea, flatulence, arthralgia, and fatigue.

Rare But Serious

Which uncommon events require urgent attention?

Rare but potentially severe events include interstitial nephritis and renal dysfunction, pancreatitis, severe allergic reactions with rash and fever, and cardiopulmonary symptoms such as chest pain or dyspnoea.

Canadian post‑market surveillance highlights the need for baseline and follow‑up renal testing, and patients developing reduced urine output, severe abdominal pain, new rash or breathing difficulties should stop the drug and seek urgent assessment.

Comparable Medicines In Canada

Alternatives Table

Which other mesalazine products might be offered as alternatives?

Comparable products include Asacol (delayed‑release), Pentasa (sustained‑release), Mezavant/Lialda (extended‑release where available), Salofalk (market‑dependent), Rowasa (rectal), and generics labelled mesalamine.

When substituting, pharmacists should compare release type, typical strengths and the listed DIN to ensure therapeutic equivalence and appropriate reimbursement where relevant.

Pros And Cons List

What are the practical advantages and disadvantages of different choices?

Pros: mesalazine products are effective for induction and maintenance in mild‑to‑moderate ulcerative colitis and offer multiple formulations to target disease location.

Cons: cost varies by brand and province, switching between release mechanisms can affect tolerability, and renal monitoring is required with long‑term use.

Choice is often driven by provincial formularies and insurance coverage, so counselling on DIN differences and excipients is important when substituting.

Current Research & Trends

Major Canadian Or International Studies 2022–2025

What are the recent research themes for mesalazine?

Recent studies and meta‑analyses from 2022–2025 looked at comparative effectiveness of release technologies, real‑world renal safety, and the role of 5‑ASA versus newer biologics for mild disease.

Evidence suggests broadly similar efficacy across formulations for many patients, but patient‑centred selection of formulation improves adherence and outcomes.

Other trends include pharmacokinetic work, targeted therapeutic drug monitoring in special populations such as pregnancy or renal impairment, and cost‑effectiveness analyses informing provincial formulary decisions.

Common Patient Questions In Canada

Is Mezavant available at my local pharmacy?

Availability varies by store; ask the pharmacist to check current stock or to order a specific brand, and expect alternatives such as Asacol or generics to be offered if Mezavant is not stocked.

Will my provincial drug plan cover it?

Coverage depends on the product’s DIN and your provincial formulary; check Ontario Drug Benefit, BC PharmaCare, RAMQ or your private plan for specifics.

Do I need blood tests?

Yes — baseline and periodic renal function tests (creatinine) are recommended while on mesalazine.

Can I take mesalazine during pregnancy?

Discuss with your prescriber; many clinicians continue 5‑ASA when the potential benefit outweighs risk and monitor as appropriate.

What if I miss a dose?

Take the missed dose as soon as remembered unless it is almost time for the next dose and do not double doses.

Regulatory Status

Health Canada Approval Process

How are mesalazine products authorised in Canada?

Drugs are approved through Health Canada’s review process and approved products hold a Drug Identification Number (DIN) and an associated product monograph describing indications, dosing and safety.

DIN Number Relevance

The DIN uniquely identifies an authorised product in Canada and is essential for provincial reimbursement, pharmacy dispensing and pharmacovigilance reporting.

Imported or U.S.‑sourced products lacking a Canadian DIN may not be eligible for coverage and can raise regulatory and safety questions, so patients should confirm the DIN on packaging and consult their pharmacist about equivalent DINs.

Visual Recommendations

Infographic Ideas For Canadian Context

Which visuals help patients decide and adhere?

Suggested assets include an infographic showing how mesalazine releases by formulation across the GI tract, a provincial pricing heatmap by pack size, and a flowchart for actions if certain symptoms occur.

Other useful visual blocks are anonymized patient quote snippets, product photos with clear DIN callouts, a downloadable PDF of provincial reimbursement links, and a comparison table showing release type, common strengths and example DINs where available.

Buying & Storage Advice

In‑Store Vs. Online Canadian Purchase Tips

What should patients check before buying mesalazine?

In store, verify the DIN, strength and release type and ask the pharmacist about interchangeability and monitoring needs.

Online, use CPhA‑accredited or well‑known Canadian pharmacies and ensure e‑prescription requirements are met at dispensing.

Beware of cross‑border purchases: U.S. labels such as Lialda may differ and might lack a Canadian DIN, potentially affecting coverage and safety reporting.

Proper Storage With Canadian Climate Considerations

How should mesalazine be stored in Canada’s seasons?

Store at 15–30°C and protect from moisture and direct sunlight.

Avoid leaving medication in vehicles during Canadian winters where freezing can occur, and avoid hot, parked cars in summer which may exceed recommended temperatures.

When travelling, carry medicines in original packaging with the pharmacy label and a copy of the prescription.

Guidelines For Proper Use

Canadian Doctor/Pharmacist Advice Style

What should pharmacy counselling cover?

Confirm the indication and review the product monograph and DIN before dispensing.

Explain the release mechanism and dosing schedule clearly and offer pill‑taking strategies for multiple daily doses or options for extended‑release formulations to improve adherence.

Emphasize renal monitoring with baseline creatinine and periodic checks, and outline symptoms that require urgent attention such as reduced urine output, severe abdominal pain, new rash, or breathing difficulty.

Coordinate prior authorisation needs with provincial drug plans, and inform patients about manufacturer assistance or coupons when available.

Delivery Across Canada (English)

Quick Practical Examples And Counselling Scenarios

Patient Switching Brands

Scenario: a patient calls because their Asacol supply is out and the local store only has Pentasa.

Counselling points include checking the DIN, explaining release differences, assessing tolerance history, and arranging baseline renal monitoring if ongoing therapy continues.

Friday Evening Prescription Need

Scenario: a new prescription is written on a Friday evening for induction dosing of 4.8 g/day.

Local pharmacists can often dispense a starter supply and advise urgent follow‑up with the prescriber and arrange necessary bloodwork early in the week.

Summary And Next Steps

If you are managing ulcerative colitis with 5‑ASA therapy, note that mesalazine is effective for induction and maintenance and comes in several release formulations suited to different disease locations.

Check availability at your local pharmacy or online, verify the DIN and coverage under your provincial plan, and arrange baseline and periodic renal monitoring as part of ongoing care.

Contact your pharmacist for specific price comparisons, ordering options, and formulary support including prior authorisation where needed.

For product‑specific details, consult the product monograph for the DIN supplied with your medication and review patient leaflets for current safety information.